Company filings, made visual.

Find a company. Follow its revenue through costs and profit.

Market

Find a company or ticker

Coverage includes separate ticker and security records; counts are not unique companies.

DexCom, Inc.

DXCM

Filing: SEC 10-Q
Period: Quarter ended 2026-03-31
Basis: Editorial filing; Read original SEC 10-Q ↗

Sankey diagram of DexCom, Inc.. A complete text table follows the diagram.

Dexcom Scales Through Distributors at Home and Direct Sales Abroad

Distributors carry 96% of U.S. glucose-monitoring revenue, while direct selling plays a much larger role in international markets

Swipe to explore

Source & review

Read original SEC 10-Q ↗

SEC accession: 0001093557-26-000073
Filed: Date not recorded
Reviewed: 2026-07-28
Status: Individual filing review complete

How to read these figures

Channel revenue includes disposable sensors and reusable hardware; the filing does not separately quantify those product types. Geographic classification reflects Dexcom's reported U.S. and international markets.

Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.

Dexcom added approximately 600,000–700,000 net customers during 2025, excluding Stelo users.
The product platform spans prescription G7 sensors and over-the-counter Stelo biosensors.
International direct revenue grew 16%; U.S. distributor revenue grew 11%.

View accessible tables

Financial categories · Quarter ended 2026-03-31 · Millions of USD
Category	Stage	Value	Notes
Distributor channel	1	$1.0B	85% of quarterly revenue
Direct sales channel	1	$182M	15% of quarterly revenue
United States	2	$832M	70% of quarterly revenue
International markets	2	$360M	30% of quarterly revenue

Financial flows · Millions of USD
From	To	Value
Distributor channel	United States	$797M
Distributor channel	International markets	$213M
Direct sales channel	United States	$35.4M
Direct sales channel	International markets	$146M